Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer

NCT04316169 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Funding and PI leaving institution

Conditions

Solid Tumor
Advanced Breast Cancer

Interventions

DRUG: Abemaciclib
DRUG: Hydroxychloroquine 200 mg
DRUG: Faslodex
DRUG: Anastrazole
DRUG: Letrozole
DRUG: Hydroxychloroquine 400 mg
DRUG: Hydroxychloroquine 600 mg

Sponsor

Medical College of Wisconsin